A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies.

Trial Profile

A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2014

At a glance

  • Drugs ZSTK 474 (Primary)
  • Indications Anal cancer; Cholangiocarcinoma; Colorectal cancer; Gynaecological cancer; Non-small cell lung cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Zenyaku Kogyo
  • Most Recent Events

    • 24 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 04 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top